Pregnant women are often positioned with taking care of themselves independently in between physician visits. Here's how a new support system empowers women's health.
Strategies to accelerate the shift from volume to value
Here’s more on how proposed modifications to CMS’ Advance Notice Summary may affect reimbursement, payment growth rates, and regulation.
In light of breaking news, the pharma value chain is definitely ripe for disruption. Here's how health plans, employers, and drug companies can adjust to the new normal.
Cybersecurity is still a foreign concept for many executives looking to avoid the next WannaCry. This new report from Marsh & McLennan and FireEye shares five cyber risk solutions for business leaders.
The talent-focused healthcare organization succeeds by investing back into the very people who help its leaders and operations surpass the competition.
Based on our analysis recently featured in the Wall Street Journal, the prevalence of no cost bronze coverage has increased significantly for 2018.
US-funded global health R&D is advancing innovations that are improving health worldwide, and it is also paying huge dividends for America.
As one of the fastest-rising categories of healthcare costs, pharmaceuticals need to develop a metric that explains pricing.
Why is the shift to value taking so long? And where are the promised results? There's nothing wrong with the model; the problem is in execution and implementation.
Now more than ever, Medicaid MCOs need the right providers in their network.